GlassScriptPhysician profile
Kevin J Vaska
NPI 1891782645
$24,046.55
in general payments reported to CMS, 2019-2025
28 companies · $1,322 in 2025
The $1,322 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,393 · 2020: $4,361 · 2021: $6,062 · 2022: $1,393 · 2023: $1,267 · 2024: $1,249 · 2025: $1,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,450 · Consulting Fee: $200 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,449.76 |
| Consulting Fee | $200.00 |
| Education | $187.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $16,781.40 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,591.52 | 2019-2025 | Lifevest |
| United Therapeutics Corporation | $969.26 | 2019-2025 | Tyvaso, Orenitram, Tyvaso |
| Janssen Pharmaceuticals, INC | $946.36 | 2019-2025 | Xarelto, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $523.76 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $344.60 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $337.86 | 2022-2025 | Winrevair, Verquvo, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $327.27 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $308.96 | 2019-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $307.49 | 2020-2025 | Camzyos, Eliquis |
| Alnylam Pharmaceuticals INC. | $279.16 | 2020-2024 | Amvuttra |
| Lundbeck LLC | $173.04 | 2019-2021 | |
| Boston Scientific Corporation | $165.37 | 2022-2025 | Watchman Flx, Watchman |
| Sanofi-Aventis U.S. LLC | $157.14 | 2019-2024 | |
| Amgen INC. | $115.01 | 2019-2024 | Repatha |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $111.63 | 2019-2025 | |
| Lexicon Pharmaceuticals, INC. | $97.02 | 2023-2024 | Inpefa |
| Itamar Medical INC | $81.34 | 2023 | Watchpatone |
| Novo Nordisk INC | $72.37 | 2023 | Ozempic, Rybelsus |
| Abbott Laboratories | $65.29 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $62.28 | 2021 | |
| Pfizer INC. | $57.80 | 2020-2024 | |
| Vifor Pharma, INC. | $52.38 | 2019-2020 | |
| Daiichi Sankyo INC. | $50.21 | 2019-2023 | Injectafer |
| Scpharmaceuticals INC. | $40.81 | 2025 | |
| Bridgebio Pharma, INC. | $15.60 | 2025 | Attruby |
| Apria Healthcare LLC | $11.62 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Vaska listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.